Myrcene

Myrcene is a monocyclic monoterpene found naturally in mangoes, hops, lemongrass, and cannabis, where it contributes to characteristic aromas and flavors. It undergoes cytochrome P450-mediated hepatic metabolism and has been studied primarily for its chemical properties, though robust human clinical evidence for health benefits remains absent.

Origin & History

Myrcene is a naturally occurring acyclic monoterpene (C₁₀H₁₆) primarily found in the essential oils of hops, mangoes, lemongrass, and various herbs. It is biosynthesized in plants through condensation of isopentenyl diphosphate and dimethylallyl diphosphate, and commercially extracted via methods including hydro-distillation, solvent extraction, and supercritical CO₂ extraction.

Historical & Cultural Context

No historical or traditional medicinal uses are documented in the available research. The sources emphasize chemical, biosynthetic, and industrial applications rather than ethnomedical contexts.

Health Benefits

• No clinical health benefits documented - research focuses solely on chemical properties and extraction methods
• Metabolic pathway identified - undergoes CYP450-mediated metabolism in rat liver microsomes (animal study only)
• Natural plant compound - found in common foods like mangoes and hops (no health claims studied)
• Essential oil component - part of complex mixtures in aromatic plants (industrial/chemical applications only)
• Biosynthetic precursor - serves as starting material in plant metabolism (no human health data)

How It Works

Myrcene is metabolized in the liver via cytochrome P450 enzymes, particularly CYP2B and CYP3A isoforms identified in rat liver microsome studies, producing epoxide and hydroxylated metabolites. Preclinical animal and in vitro studies suggest it may interact with GABA-A receptors and opioid signaling pathways, which could partly explain sedative-like observations in rodent models. It also demonstrates inhibition of pro-inflammatory enzymes including COX-1 and COX-2 in isolated cell assays, though no confirmed receptor-binding affinity data from human tissue is available.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses on myrcene were identified in the available research. The provided sources focus exclusively on chemical properties, biosynthesis, extraction methods, and polymerization rather than human health studies.

Clinical Summary

No published randomized controlled trials or peer-reviewed human clinical studies have evaluated myrcene as an isolated supplement for any health outcome. The available evidence consists of animal studies, including rodent models showing analgesic and sedative effects at doses of 200 mg/kg — doses not directly translatable to humans — and in vitro cell-culture experiments. A pharmacokinetic study using rat liver microsomes confirmed CYP450-mediated metabolism, establishing a metabolic pathway but not a therapeutic indication. The overall evidence base is preclinical and insufficient to support any health claim for human supplementation.

Nutritional Profile

Myrcene (β-myrcene, C₁₀H₁₆) is a monoterpene hydrocarbon, not a nutrient per se, so it lacks macronutrients, vitamins, or minerals. It is a major bioactive volatile compound found at high concentrations in hop essential oil (up to 29-50% of total oil), mango flesh (contributing to aroma), lemongrass (~12-25% of essential oil), bay laurel, and cannabis. Typical dietary exposure from foods is trace-level (microgram to low milligram range). As a lipophilic terpene (log P ~4.17), it has moderate oral bioavailability but is rapidly metabolized via hepatic CYP2B enzymes to hydroxylated metabolites (e.g., myrcene-10-ol, myrcene-1,2-diol). It is classified as a secondary plant metabolite with no caloric or micronutrient value.

Preparation & Dosage

No clinically studied dosage ranges or standardized forms have been established for myrcene supplementation. The research does not provide human dosing data, safety parameters, or therapeutic recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Myrcene pairs synergistically with β-caryophyllene (a sesquiterpene from black pepper and cloves) and limonene (from citrus peel), as these three terpenes together enhance mutual absorption across biological membranes — myrcene specifically is proposed to increase cell membrane permeability, potentially improving the bioavailability of co-administered compounds. Linalool (from lavender) complements myrcene's sedative-adjacent profile in aromatherapy contexts, and the combination with humulene (α-caryophyllene, abundant in hops alongside myrcene) may produce additive effects in modulating inflammatory pathways via CB2 receptor and PPARγ interactions. Additionally, pairing with a lipid carrier such as MCT oil (medium-chain triglycerides) significantly improves myrcene's oral bioavailability given its high lipophilicity and susceptibility to first-pass metabolism.

Safety & Interactions

Human safety data for isolated myrcene supplementation is essentially nonexistent, as no formal phase I or phase II clinical safety trials have been conducted. Because myrcene is metabolized by CYP2B and CYP3A enzymes, theoretical drug interactions exist with medications sharing these pathways, including certain statins, benzodiazepines, and immunosuppressants, though no interaction studies in humans have been published. Myrcene is classified as GRAS (Generally Recognized As Safe) by the FDA at the low concentrations present in food flavorings, but concentrated supplemental doses have not been evaluated for safety in pregnant or lactating individuals, and use should be avoided in those populations until data exist. Individuals taking CNS depressants should exercise caution given preliminary rodent data suggesting potentiation of sedative effects.